Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 78.3% in February

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 500 shares, a decrease of 78.3% from the January 31st total of 2,300 shares. Based on an average trading volume of 11,700 shares, the days-to-cover ratio is currently 0.0 days.

Fortress Biotech Stock Performance

Fortress Biotech stock opened at $5.93 on Friday. The business has a 50-day moving average of $6.64 and a 200-day moving average of $6.13. Fortress Biotech has a 1 year low of $4.86 and a 1 year high of $18.00.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.